Trial Search Results

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Robert Negrin

Collaborator: National Institutes of Health (NIH)

Stanford Investigator(s):


  • Drug: Cytokine Induced Killer Cells


Phase 1


Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following
HLA matched allogeneic hematopoietic cell transplant

   - eligible for DLI

   - no evidence of GVHD

   - stable immunosuppressive regimen

   - adequate renal and liver function Exclusion Criteria:- CML patients who have not
   received DLI, active infections

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
Not Recruiting